instant bio.
instant bio. builds vascularized organoid chip platforms that integrate human blood perfusion to better mimic human tissue function for preclinical drug development. The platform combines organoid biology with microfluidic chip technology, enabling researchers to observe drug responses in a dynamic, vascularized environment and improve predictions of efficacy, metabolism, and toxicity before human trials.
- Biotechnology
- Drug Discovery & Therapeutics
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Traditional two-dimensional cell cultures and simplified organoid models lack the vascular networks and blood flow necessary to mimic human physiology. This limitation reduces the predictive accuracy of preclinical drug testing, leading to costly late-stage failures in clinical development.
Solution
instant bio. provides vascularized organoid chip platforms that incorporate human blood perfusion, creating a more faithful representation of human tissue function for drug development. The platform combines organoid biology with microfluidic chip technology, allowing researchers to observe drug responses in a dynamic, vascularized environment. This approach supports more reliable assessment of drug efficacy, metabolism, and toxicity prior to human trials. The system is designed to bridge the gap between traditional in vitro models and in vivo outcomes, helping pharmaceutical and biotech companies make better-informed decisions earlier in the pipeline.
Target Audience
Primary customers are pharmaceutical companies, biotechnology firms, and contract research organizations conducting preclinical drug efficacy and safety assessments.
Features
- Human organoid chip platform with integrated vascular networks for physiologically relevant in vitro modeling
- Human blood perfusion capability to simulate systemic drug exposure and circulation dynamics
- Microfluidic design enabling controlled, reproducible culture conditions across experiments
- Compatibility with standard assays and imaging workflows for readouts of efficacy and toxicity